Biomarkers to Evaluate Therapies that Target the Immune System in Early-Stage Alzheimer’s Trials: Patient Selection, Target Engagement, & Promising Technologies

Time: 11:15 am
day: Day Two


  • Biomarkers to select patients most likely to respond to treatment
  • Using Biomarkers to determine target engagement and demonstrate safety; inflammatory biomarkers are not enough
  • Non-invasive biomarkers to predict treatment response